Abstract
The risk of life-threatening complications associated with angioplasty are significantly reduced by a single dose of Centocor’s glycoprotein IIb/IIIa receptor antagonist abciximab [c7E3], compared with placebo, according to the results of the EPILOG * and CAPTURE * trials, and the latest results from the EPIC * study. The EPILOG and CAPTURE trials were terminated early due to the obvious treatment-associated clinical benefits that were seen during interim analyses. Data from the analyses were presented at the 18th Congress of the European Society of Cardiology (ESC) [ Birmingham, UK; August 1996 ]. In another study presented at the conference, referred to as ISAR * , researchers showed that adjunctive antiplatelet therapy provided greater clinical benefit than anticoagulant therapy in patients undergoing intracoronary stent placement.
Rights and permissions
About this article
Cite this article
Jack, D.B. New trials support use of abciximab in PTCA. Inpharma Wkly. 1053, 3–4 (1996). https://doi.org/10.2165/00128413-199610530-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-199610530-00003